FIELD: chemistry.
SUBSTANCE: invention concerns compound of formula (I) 
where Ry is 
, or its pharmaceutically acceptable salts. These compounds have phosphodiesterase (PDE) inhibition effect, particularly for PDE-4. Additionally invention claims application of compound of the formula (I) or its pharmaceutically acceptable salt in manufacturing of medicine for treatment and/or prevention of cognitive ability depression or disorder of humans, e.g. of chronic neurological disorder, such as Alzheimer's disease.
EFFECT: enhanced efficiency of composition and treatment method.
17 cl, 21 tbl, 191 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRAZOLO[3,4-b]PURIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITION (VERSIONS), APPLICATION (VERSIONS), COMBINATION (VERSIONS) | 2003 |
|
RU2357967C2 |
| SERINE/THREONINE KINASE INHIBITORS | 2013 |
|
RU2650501C2 |
| AZAINDAZOLE OR DIAZAINDAZOLE DERIVATIVES AS MEDICINE | 2012 |
|
RU2600976C2 |
| METHODS OF OBTAINING AND PURIFICATION OF HETEROARYL COMPOUNDS | 2010 |
|
RU2557242C2 |
| PIPERIDINE DERIVATIVES | 2011 |
|
RU2554353C2 |
| NOVEL DERIVATIVE OF PURINYLPYRIDINYLAMINO-2,4-DIFLUOROPHENYLSULPHONAMIDE, ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHOD OF ITS OBTAINING AND PHARMACEUTICAL COMPOSITION, WHICH HAS INHIBITION ACTIVITY WITH RESPECT TO RAF-KINASE, CONTAINING CLAIMED COMPOUND AS ACTIVE INGREDIENT | 2011 |
|
RU2550038C2 |
| mTOR KINASE INHIBITORS FOR ONCOLOGICAL INDICATIONS AND DISEASES METABOLICALLY BOUND TO mTOR/PI3K/AKT | 2009 |
|
RU2546658C2 |
| DERIVATIVES OF AZAINDASOLE OR DIAZAINDASOLE TYPE FOR PAIN TREATMENT | 2013 |
|
RU2640046C2 |
| SUBSTITUTED 2H-PYRANO[2,3-C]PYRIDINES, COMBINATORY AND FOCUSED LIBRARIES | 2003 |
|
RU2261251C2 |
| NEW COMPOUNDS FOR TREATING AMYLOID OR AMYLOID-LIKE PROTEIN ASSOCIATED DISEASES | 2007 |
|
RU2469026C2 |
